


# The Evolution of Design




**PERFORMANCE** through innovation

Gore continues to modify the GORE® VIABAHN® Endoprosthesis, demonstrating the company's commitment to providing its customers with innovative devices for treating Peripheral Arterial Disease.

Now  
Available in  
**6 Fr**





## Lower French Sizes on Specific Configurations

- Reduced delivery profile on 5 – 8 mm

DIAMETER (mm)	PROFILE (Fr)	GUIDEWIRE
5	6	0.014" or 0.018"
6	6	0.014" or 0.018"
7	7	0.014" or 0.018"
8	7	0.014" or 0.018"


- New catheter design maintains pushability and trackability of previous generation

## Streamlined Deployment for All Configurations: 5 – 13 mm diameters

- 0.035" guidewire compatibility for streamlined delivery
- TIP to HUB deployment
- Radial endoprosthesis expansion

## CARMEDA® BioActive Surface (CBAS®)

- Intended to provide a thromboresistant surface
- Proprietary end-point covalent bonding
- Sustained Heparin bioactivity\*



Long-term Heparin Activity of Explanted Heparin-bonded ePTFE Vascular Grafts in a Canine Model\*

\* Begovac PC, Thomson RC, Fisher JL, Hughson A, Gällhagen A. Improvements in GORE-TEX® Vascular Graft performance by Carmeda® bioactive surface heparin immobilization. *European Journal of Vascular and Endovascular Surgery* 2003;25(5):432-437.



**W. L. GORE & ASSOCIATES, INC.**  
Flagstaff, AZ 86004

+65.67332882 (Asia Pacific)  
00800.6334.4673 (Europe)  
800.437.8181 (United States)  
928.779.2771 (United States)

[goremedical.com](http://goremedical.com)

Consult Instructions for Use

Products listed may not be available in all markets.  
GORE®, HEMOBAHN®, PERFORMANCE THROUGH INNOVATION, TIP to HUB, VIABAHN®, and designs are trademarks of W. L. Gore & Associates. CARMEDA® and CBAS® are trademarks of Carmeda AB, a wholly owned subsidiary of W. L. Gore & Associates.  
© 2010, 2011 W. L. Gore & Associates, Inc.  
AQ0099-EN1 FEBRUARY 2011

**INTENDED USE / INDICATIONS** The GORE® VIABAHN® Endoprosthesis is indicated for improving blood flow in patients with symptomatic peripheral arterial disease in superficial femoral artery lesions with reference vessel diameters ranging from 4.0 – 7.5 mm. The GORE® VIABAHN® Endoprosthesis is indicated for improving blood flow in patients with symptomatic peripheral arterial disease in iliac artery lesions with reference vessel diameters ranging from 4.0 – 12 mm. **CONTRAINDICATIONS** The GORE® VIABAHN® Endoprosthesis is contraindicated for non-compliant lesions where full expansion of an angioplasty balloon catheter was not achieved during pre-dilatation, or where lesions cannot be dilated sufficiently to allow passage of the delivery system. Do not use the GORE® VIABAHN® Endoprosthesis with Heparin Bioactive Surface in patients with known hypersensitivity to heparin, including those patients who have had a previous incidence of Heparin-Induced Thrombocytopenia (HIT) type II. Only